Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All bamlanivimab/etesevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 67% Improvement Relative Risk Death/hospitalization 64% primary Hospitalization 61% Bamlanivimab/e..  Bariola et al.  LATE TREATMENT Is late treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 468 patients in the USA Lower death/hosp. (p=0.00029) and hospitalization (p=0.001) c19early.org Bariola et al., medRxiv, March 2021 Favors bamlanivimab/e.. Favors control

Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection

Bariola et al., medRxiv, doi:10.1101/2021.03.25.21254322
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
23rd treatment shown to reduce risk in June 2021
 
*, now known with p = 0.0005 from 17 studies, recognized in 3 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 234 patients receiving bamlanivimab and 234 matched controls, showing lower hospitalization and mortality with treatment. Greater benefit was seen with administration within 4 days of their positive COVID-19 test.
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene c19early.org, c19early.org (B), vitamin D c19early.org (C), etc.) — either because the physician recommending bamlanivimab/etesevimab also recommended them, or because the patient seeking out bamlanivimab/etesevimab is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate the efficacy of treatments.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron Haars, Liu, Pochtovyi, Sheward, VanBlargan.
risk of death, 66.8% lower, RR 0.33, p = 0.05, treatment 4 of 234 (1.7%), control 12 of 234 (5.1%), NNT 29, odds ratio converted to relative risk.
risk of death/hospitalization, 64.3% lower, RR 0.36, p < 0.001, treatment 16 of 234 (6.8%), control 45 of 234 (19.2%), NNT 8.1, odds ratio converted to relative risk, primary outcome.
risk of hospitalization, 60.7% lower, RR 0.39, p = 0.001, treatment 15 of 234 (6.4%), control 39 of 234 (16.7%), NNT 9.8, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bariola et al., 30 Mar 2021, retrospective, USA, preprint, 22 authors.
This PaperBamlaniv../e..All
Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
J Ryan Bariola, PharmD Erin K Mccreary, MD Richard J Wadas, PhD Kevin E Kip, MD Oscar C Marroquin, MSN Tami Minnier, BS Stephen Koscumb, BS Kevin Collins, MD Mark Schmidhofer, Judith A Shovel, MT Mary Kay Wisniewski, Colleen Sullivan, MD Donald M Yealy, MD MPH David A Nace, MD MPH David T Huang, MD Ghady Haidar, Tina Khadem, MS Kelsey Linstrum, MD MSc Christopher W Seymour, MS Stephanie K Montgomery, MD MPH FRCP Derek C Angus, MD SM Graham M Snyder
doi:10.1101/2021.03.25.21254322
Background: Monoclonal antibody (mAb) treatment may prevent complications of COVID-19. We sought to quantify the impact of bamlanivimab monotherapy on hospitalizations and mortality, as well as Emergency Department (ED) visits without hospitalization, among outpatients at high risk of COVID-19 complications. Methods: We compared patients receiving mAb to patients who met criteria but did not receive mAb from December 2020 through March 2021. The study population selection used propensity scores to match 1:1 by likelihood to receive mAb. The primary outcome was hospitalization or all-cause mortality within 28 days; the secondary outcome was hospitalization or ED visit without hospitalization within 28 days. Odds ratios (OR) calculation used logistic regression modeling including propensity score and mAb receipt predictors. Results: The study population included 234 patients receiving mAb and 234 matched comparator patients not receiving mAb. Patients receiving mAb were less likely to experience hospitalization or mortality (OR 0.31, 95% confidence interval [95%CI] 0.17-0.56, p=0.00001) and hospitalization or ED visit without hospitalization (OR 0.50, 95%CI 0.43-0.83, p=0.007). The impact of mAb was more pronounced in prevention of hospitalization (among all age groups, OR 0.35, 95%CI 0.19-0.66, p=0.001) than mortality or ED visit without hospitalization, and most strongly associated with patients age 65 years and older (primary outcome OR 0.28, 95%CI 0.14-0.56, p=0.0003). Conclusions : Bamlanivimab monotherapy was associated with reduction in the composite outcome of hospitalizations and mortality in patients with mild-moderate COVID-19. The benefit may be strongest in preventing hospitalization in patients ages 65 years or older. . CoV016; Eli Lilly), casirivimab 1,200mg (REGN10933; Regeneron), imdevimab 1,200mg (REGN10987). Several clinical trials currently evaluate mAbs for prevention or treatment of COVID-19; however, real-world data are limited, and the role of mAbs for patients with COVID-19 remains controversial. 3, 5 Use of mAb therapy is low in the United States despite widespread drug availability due to lack of robust efficacy data, operational challenges with outpatient infusions, and patient access issues. 6 Our health system established a mAb program in November 2020 to decrease COVID-19-related complications for patients with mild-moderate illness and expand access to care for underserved patients with COVID-19. Initially, only bamlanivimab monotherapy was available; our evaluation and distribution process has been described elsewhere. 7 This study quantifies the impact of bamlanivimab monotherapy on hospitalizations, mortality, and Emergency Department (ED) visits among outpatients at high risk of progressing to severe COVID-19. We also explored whether patient age, body mass index, and timing of infusions relative to initial diagnosis had any association with response to therapy. METHODS Study Setting .
Conflict of Interest Disclosure: None of the authors received any payments or influence from a third-party source for the work presented, and none report any potential conflicts of interest. SUPPLEMENTAL MATERIALS
References
Ault, Rollout of COVID Monoclonal Antibodies Lacked Unified Plan: Expert Panel
Austin, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies, Multivariate Behav Res. May, doi:10.1080/00273171.2011.568786
Bajaj, Gadi, Spihlman, Wu, Choi et al., Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?, Front Physiol, doi:10.3389/fphys.2020.571416
Bariola, Mccreary, Khadem, Snyder, Wadas et al., Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic, Open Forum Infect Dis
Benchimol, Smeeth, Guttmann, The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement, PLoS Med, doi:10.1371/journal.pmed.1001885
Chen, Nirula, Heller, SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2029849
Cohen1, Nirula2, Mulligan3, Novak4, Marovich5 et al., ). Bamlanivimab prevents COVID-19 morbidity and mortality in nursinghome setting
Gottlieb, Nirula, Chen, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, Jama, doi:10.1001/jama.2021.0202
Jones, Brown-Augsburger, Corbett, LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection, bioRxiv, doi:10.1101/2020.09.30.318972
Lim, Subramaniam, Reddy, Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis, Am J Respir Crit Care Med. Jan, doi:10.1164/rccm.202006-2405OC
Liu, Wei, Zhang, V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro, bioRxiv, doi:10.1101/2021.02.16.43130519
Reitz, Marroquin, Zenati, Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes, JAMA Surg. Jun, doi:10.1001/jamasurg.2020.0416
Richardson, Hirsch, Narasimhan, Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA, doi:10.1001/jama.2020.6775
Rosenbaum, Db, The central role of the propensity score in observational studies for causal effects, Biometrika, doi:10.1093/biomet/70.1.41
Tartof, Qian, Hong, Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization, Ann Intern Med. Nov, doi:10.7326/m20-3742
Webb, Buckel, Vento, Real-World Effectiveness and Tolerability of Monoclonal Antibodies for Ambulatory Patients with Early COVID-19, doi:10.1101/2021.03.15.21253646
Weinreich, Sivapalasingam, Norton, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2035002
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit